SCHEMBL15068544

SCHEMBL15068544

CCOc1c(N2CCCCC2)c2c(O)cccc2oc1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.41
ALDH1A1 P00352 4/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 3/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 2/20 0.40
AGTR1 P30556 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
CCR4 P51679 3/20 0.37
CREB1 P16220 1/20 0.37
NMT2 O60551 1/20 0.36
NMT1 P30419 1/20 0.36
PGAM1 P18669 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16671606 0.99 MAPT (0.41) GAAALDH1A1KMT2ALMNATSHR
SCHEMBL15068641 0.78 MAPT (0.46) GAAALDH1A1KMT2ALMNATSHR
SCHEMBL6273104 0.78 CREB1 (0.49) GAAALDH1A1KMT2ALMNAHSD17B10
SCHEMBL16671722 0.68 CCR4 (0.50) ALDH1A1KMT2ALMNAHSD17B10MAPT
SCHEMBL15068546 0.68 KMT2A (0.42) GAAALDH1A1KMT2ALMNATSHR
SCHEMBL6277225 0.67 POLH (0.45) LMNAHTTMAPTNPC1RAB9A
SCHEMBL16671607 0.67 KMT2A (0.41) GAAALDH1A1KMT2ALMNATSHR
SCHEMBL15069249 0.66 GAA (0.49) GAAALDH1A1KMT2ALMNATSHR
SCHEMBL8489727 0.66 ALOX5 (0.47) PGAM1POLH
SCHEMBL15068746 0.66 ALDH1A1 (0.49) GAAALDH1A1KMT2ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 GAA 447/4885ALDH1A1 1006/4885KMT2A 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.